The clotting cascade and platelets interplay in thrombus formation during acute coronary syndromes. Accordingly, the combination of anticoagulants and antiplatelets could be an interesting approach to minimize ischemic complications in the acute and chronic phases of acute coronary syndromes. Currently, there are no data supporting the combination of new P2 Y12-receptor inhibitors (ticagrelor and prasug-rel) and non-vitamin K antagonist oral anticoagulants in the long-term treatment after an acute coro-nary syndrome. An intriguing option could be the association of ticagrelor and non-vitamin K antagonist oral anticoagulants, without aspirin, but future studies are clearly required.
What are the recommendations for adding novel oral anticoagulants to P2Y12-receptor inhibitors, with or without aspirin?
Campo G.;Biscaglia S.;Fileti L.;Pavasini R.
2015
Abstract
The clotting cascade and platelets interplay in thrombus formation during acute coronary syndromes. Accordingly, the combination of anticoagulants and antiplatelets could be an interesting approach to minimize ischemic complications in the acute and chronic phases of acute coronary syndromes. Currently, there are no data supporting the combination of new P2 Y12-receptor inhibitors (ticagrelor and prasug-rel) and non-vitamin K antagonist oral anticoagulants in the long-term treatment after an acute coro-nary syndrome. An intriguing option could be the association of ticagrelor and non-vitamin K antagonist oral anticoagulants, without aspirin, but future studies are clearly required.I documenti in SFERA sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
